Novelion Therapeutics (NVLN)

Novelion Therapeutics (NVLN) is a global bio-pharmaceutical company that develops transformational therapies that have the potential to significantly change the treatment paradigm for patients affected by a variety of rare and metabolic diseases, including diseases associated with low leptin, such as low-leptin associated obesity. 

On Friday, NVLN reported 3rd quarter earnings and beat analysts estimates by .17. The stock price is reflecting that big earnings win trading up over 50% on Friday. I like NVLN to retest Thursday high of 2.35 and to possibly have more continuation next week.